HARTE-HANKS INC (HHS) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:HHS • US4161962026

3.12 USD

+0.06 (+1.96%)

Last: Jan 29, 2026, 08:24 PM

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to HHS. HHS was compared to 92 industry peers in the Media industry. HHS has only an average score on both its financial health and profitability. HHS is valued correctly, but it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

HHS had negative earnings in the past year.
HHS had a positive operating cash flow in the past year.
In multiple years HHS reported negative net income over the last 5 years.
In multiple years HHS reported negative operating cash flow during the last 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -5.86%, HHS is in line with its industry, outperforming 46.74% of the companies in the same industry.
HHS's Return On Equity of -27.25% is in line compared to the rest of the industry. HHS outperforms 45.65% of its industry peers.
Looking at the Return On Invested Capital, with a value of 5.17%, HHS is in the better half of the industry, outperforming 70.65% of the companies in the same industry.
HHS had an Average Return On Invested Capital over the past 3 years of 11.53%. This is above the industry average of 7.07%.
The last Return On Invested Capital (5.17%) for HHS is well below the 3 year average (11.53%), which needs to be investigated, but indicates that HHS had better years and this may not be a problem.

		Industry Rank	Sector Rank
ROA	-5.86%
ROE	-27.25%
ROIC	5.17%

ROA(3y)-0.4%

ROA(5y)1.73%

ROE(3y)14.69%

ROE(5y)N/A

ROIC(3y)11.53%

ROIC(5y)N/A

1.3 Margins

The Operating Margin of HHS (2.36%) is comparable to the rest of the industry.
HHS's Operating Margin has declined in the last couple of years.
The Gross Margin of HHS (18.47%) is worse than 72.83% of its industry peers.
HHS's Gross Margin has improved in the last couple of years.

		Industry Rank	Sector Rank
OM	2.36%
PM (TTM)	N/A
GM	18.47%

OM growth 3Y-15.64%

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y2.08%

GM growth 5Y15.62%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so HHS is still creating some value.
HHS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, HHS has more shares outstanding
Compared to 1 year ago, HHS has a worse debt to assets ratio.

2.2 Solvency

HHS has an Altman-Z score of 14.55. This indicates that HHS is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 14.55, HHS belongs to the top of the industry, outperforming 98.91% of the companies in the same industry.
HHS has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
With an excellent Debt to Equity ratio value of 0.03, HHS belongs to the best of the industry, outperforming 83.70% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.03
Debt/FCF	N/A
Altman-Z	14.55

ROIC/WACC0.59

WACC8.81%

2.3 Liquidity

HHS has a Current Ratio of 1.48. This is a normal value and indicates that HHS is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of HHS (1.48) is better than 60.87% of its industry peers.
HHS has a Quick Ratio of 1.48. This is a normal value and indicates that HHS is financially healthy and should not expect problems in meeting its short term obligations.
HHS's Quick ratio of 1.48 is fine compared to the rest of the industry. HHS outperforms 63.04% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.48
Quick Ratio	1.48

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

HHS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 82.01%, which is quite impressive.
Looking at the last year, HHS shows a very negative growth in Revenue. The Revenue has decreased by -11.07% in the last year.
The Revenue has been decreasing by -3.17% on average over the past years.

EPS 1Y (TTM)82.01%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-1650%

Revenue 1Y (TTM)-11.07%

Revenue growth 3Y-1.63%

Revenue growth 5Y-3.17%

Sales Q2Q%-17.03%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y131.2%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year4.05%

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

HHS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
HHS is valuated cheaply with a Price/Forward Earnings ratio of 2.89.
95.65% of the companies in the same industry are more expensive than HHS, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of HHS to the average of the S&P500 Index (25.72), we can say HHS is valued rather cheaply.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	2.89

4.2 Price Multiples

HHS's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. HHS is cheaper than 97.83% of the companies in the same industry.